Banys-Paluchowski Malgorzata, Paluchowski Peter
Department of Gynecology and Obstetrics, Asklepios-Klinik Hamburg Barmbek, Hamburg 22307, Germany.
Department of Gynecology and Obstetrics, Regio Klinikum Pinneberg, Pinneberg 25421, Germany.
Cancer Drug Resist. 2019 Dec 19;2(4):1062-1068. doi: 10.20517/cdr.2019.84. eCollection 2019.
The spread of single tumor cells shed by the primary tumor has been observed in most solid carcinomas and is generally associated with poor clinical outcome. Tumor cells detected in the peripheral blood are commonly referred to as circulating tumor cells (CTCs) and are seen as possible precursors of metastatic disease. Beyond CTCs, circulating tumor DNA and non-coding RNA are increasingly the focus of translation cancer research. In metastatic breast cancer (MBC), elevated levels of CTCs have been confirmed as an independent prognostic factor. While detection of elevated counts after the start of systemic therapy predicts poor response, it is unclear which treatment strategy should be offered in the case of CTC persistence. Currently, the main potentials of blood-based diagnostics in BC are therapy monitoring and liquid biopsy-based treatment interventions. Recently, the first positive study on CTC-guided therapy choices in hormone receptor positive HER2 negative MBC was published. In the present review, we discuss the current data and potential clinical application of liquid biopsy in the metastatic setting.
在大多数实体癌中都观察到了原发性肿瘤脱落的单个肿瘤细胞的扩散，这通常与不良的临床结果相关。在外周血中检测到的肿瘤细胞通常被称为循环肿瘤细胞（CTC），并被视为转移性疾病的可能前体。除了CTC，循环肿瘤DNA和非编码RNA越来越成为转化癌症研究的焦点。在转移性乳腺癌（MBC）中，CTC水平升高已被确认为一个独立的预后因素。虽然在全身治疗开始后检测到计数升高预示着反应不佳，但在CTC持续存在的情况下应采用哪种治疗策略尚不清楚。目前，基于血液的诊断在乳腺癌中的主要潜力在于治疗监测和基于液体活检的治疗干预。最近，关于激素受体阳性HER2阴性MBC中CTC指导治疗选择的第一项阳性研究发表了。在本综述中，我们讨论了液体活检在转移性疾病中的当前数据和潜在临床应用。
